The EXSCEL (Examining Cardiovascular Outcomes with Exenatide Extended Release) trial was a major study that sought to evaluate the cardiovascular safety and efficacy of exenatide extended-release (ER), a GLP-1 RA, in patients with type-2 diabetes [80]. Here, GCG is linked to type 2 diabetes mellitus.